What Are DHA and EPA — and Why Does the Aging Brain Depend on Them?
Omega-3 polyunsaturated fatty acids (PUFAs) are a family of long-chain fats defined by a double bond at the third carbon from the methyl end. The two biologically critical forms are docosahexaenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3). Both are classified as "conditionally essential" — the human body can technically synthesize them from the plant-derived precursor alpha-linolenic acid (ALA), but conversion efficiency in adults is below 5%, making dietary or supplemental intake functionally essential for maintaining optimal tissue levels.
DHA is the dominant structural fatty acid in the central nervous system. It comprises approximately 30–40% of the phospholipid composition of neuronal membranes, concentrated in the synaptic plasma membranes, dendritic arbors, and photoreceptors. This abundance is not coincidental: DHA's 22-carbon chain with six double bonds creates extraordinary membrane fluidity, enabling the rapid conformational changes required by G-protein-coupled receptors, ion channels, and the rhodopsin photoreceptor system. As neurons age, membrane DHA content declines — a process measurably accelerated in Alzheimer's disease (AD) and other neurodegenerative conditions.
EPA serves a complementary but distinct role. While less abundant in neural tissue, EPA is the precursor to Series-3 prostaglandins, thromboxane A3, and leukotrienes B5 — anti-inflammatory eicosanoids that directly compete with the pro-inflammatory Series-2 products derived from arachidonic acid (AA). By displacing AA from membrane phospholipids, EPA shifts the inflammatory tone of virtually every tissue type. This is particularly relevant to aging: chronic low-grade inflammation (now termed "inflammaging") drives atherosclerosis, neurodegeneration, metabolic disease, and sarcopenia — making EPA's anti-inflammatory action directly relevant to healthspan extension.
Recommended: High-Purity Omega-3 Fish Oil
Look for a product providing ≥1,000 mg combined EPA+DHA per serving, from molecularly distilled fish oil with third-party purity certification (IFOS or NSF).
As an Amazon Associate, LongevityLab earns from qualifying purchases. This does not affect our editorial recommendations.
Cardiovascular Mechanisms: How Omega-3s Protect the Aging Heart
The cardiovascular case for omega-3s is built on five distinct mechanisms, each with independent clinical evidence, that collectively explain why populations with high marine fat intake — from Greenlandic Inuit to Japanese coastal communities — consistently show lower rates of coronary heart disease despite high overall fat intake.
1. Triglyceride Reduction
High-dose EPA+DHA (≥2 g/day) reduces plasma triglycerides by 15–30% in a dose-dependent manner, primarily by suppressing hepatic VLDL-TG secretion and increasing lipoprotein lipase activity. This effect is well-established in FDA-approved prescriptions: Vascepa (icosapentaenoic acid ethyl ester, 4 g/day) and Lovaza (EPA+DHA ethyl esters, 4 g/day) are both approved for severe hypertriglyceridemia.
2. Anti-Platelet and Antithrombotic Effects
EPA competes with arachidonic acid for cyclooxygenase (COX), producing thromboxane A3 (a weak platelet aggregator) instead of thromboxane A2 (a potent aggregator). The net effect is reduced platelet aggregation and lower risk of arterial thrombosis — a key mechanism in the Inuit population studies that sparked omega-3 cardiovascular research in the 1970s (Bang & Dyerberg, 1972).
3. Blood Pressure Reduction
A 2014 meta-analysis of 70 RCTs (Miller et al., American Journal of Hypertension) found omega-3 supplementation reduced systolic blood pressure by 1.52 mmHg and diastolic by 0.99 mmHg on average, with greater effects in hypertensive populations. Mechanisms include endothelial nitric oxide upregulation and reduced vasoconstrictor eicosanoid production.
4. Anti-Arrhythmic Properties
DHA and EPA stabilize cardiomyocyte membranes by modulating sodium and calcium channel kinetics, reducing the risk of fatal ventricular arrhythmias. This is thought to underlie the early separation of cardiovascular mortality curves in omega-3 trials — deaths from sudden cardiac arrest are reduced before structural plaque changes would manifest.
5. Anti-Inflammatory Endothelial Protection
Chronic arterial inflammation drives atherosclerotic plaque development. Omega-3s reduce expression of VCAM-1, ICAM-1, and E-selectin in endothelial cells — adhesion molecules that recruit monocytes to the vessel wall. They also generate resolvins and protectins, specialized pro-resolving mediators (SPMs) that actively terminate inflammatory cascades rather than merely suppressing them.
Brain Aging, Cognitive Decline, and Neuroprotection: The DHA Evidence Base
The brain is the organ most structurally dependent on DHA. From fetal neurodevelopment through late-life cognitive function, maintaining adequate brain DHA status appears to be a fundamental requirement for neurological resilience. As we age, the mechanisms maintaining brain DHA accretion become less efficient — and the consequences of DHA deficiency become more severe.
Observational epidemiology is striking: a 2022 meta-analysis published in JAMA Network Open (Yassine et al.) pooling 14 prospective cohort studies found that higher dietary DHA intake was associated with a 25% lower risk of Alzheimer's disease. The association was strongest in APOE-ε4 non-carriers, though APOE-ε4 carriers with higher baseline omega-3 status still showed attenuation of risk. A separate analysis of the Framingham Heart Study found plasma DHA in the highest quartile associated with a 47% lower risk of all-cause dementia compared to the lowest quartile (Schaefer et al., 2006, Archives of Neurology).
Intervention trials in cognitively healthy older adults have produced more heterogeneous results, largely because cognitive decline trials require very long follow-up periods and are confounded by baseline omega-3 status. However, several findings stand out:
- The MIDAS trial (Yurko-Mauro et al., 2010) found 900 mg/day DHA over 24 weeks significantly improved learning and memory in adults with age-related cognitive decline versus placebo.
- The PreventE3 trial (Danthiir et al., 2018) showed 1.67 g/day DHA+EPA improved processing speed and working memory in healthy older adults over 18 months.
- Neuroimaging studies using MRI demonstrate that higher erythrocyte DHA is associated with greater total brain volume, gray matter volume, and hippocampal volume — structures most vulnerable to Alzheimer's disease (Pottala et al., 2014, Neurology).
Mechanistically, DHA protects neurons through multiple pathways: reducing amyloid-beta (Aβ) production by modulating BACE1 activity; promoting clearance of Aβ through enhanced microglial phagocytosis; upregulating BDNF (brain-derived neurotrophic factor) expression; and generating neuroprotectin D1 (NPD1), a DHA-derived compound that inhibits pro-apoptotic gene expression in neurons exposed to Aβ42 (Bazan et al., 2011).
Major Clinical Trials: What the Evidence Actually Shows
Interpreting omega-3 trial data requires understanding a critical confound: most "null" trials enrolled populations with already-adequate omega-3 status. Studies that stratified by baseline omega index (the percentage of EPA+DHA in red blood cell membranes) consistently find the largest benefits in omega-3-deficient individuals — which in North America describes the majority of the population.
| Trial | Dose / Form | Population (N) | Duration | Key Outcome |
|---|---|---|---|---|
| VITAL (Manson et al., 2019, NEJM) | 1 g/day EPA+DHA (fish oil) | 25,871 healthy adults ≥50 | 5.3 years | 28% reduction in MI in fish non-consumers; 19% reduction in all cardiovascular events in Black participants |
| REDUCE-IT (Bhatt et al., 2019, NEJM) | 4 g/day EPA-only (icosapentaenoic acid ethyl ester) | 8,179 statin users with elevated TG | 4.9 years | 25% relative risk reduction in MACE; 20% reduction in CV death |
| ASCEND (ASCEND Study Group, 2018, NEJM) | 1 g/day EPA+DHA | 15,480 diabetics without known CVD | 7.4 years | Borderline non-significant 11% reduction in MACE; 17% reduction trend in CV death |
| STRENGTH (Nicholls et al., 2020, JAMA) | 4 g/day EPA+DHA (carboxylic acid form) | 13,078 statin users, high TG | 3+ years | Null result; terminated early — mineral oil placebo may have inflated control-arm lipids in REDUCE-IT comparison |
| MIDAS (Yurko-Mauro et al., 2010) | 900 mg/day DHA (algae) | 485 adults ≥55 with cognitive complaints | 24 weeks | Significant improvement in immediate recall and learning; paired associate learning equivalent to 3.4 years younger |
| ORIGIN (Bosch et al., 2012, NEJM) | 1 g/day EPA+DHA | 12,536 dysglycemia patients | 6.2 years | Null on MACE; significant triglyceride reduction; no harm signals |
The emerging interpretation of this trial landscape: dose matters, form matters, and baseline status matters. Low-dose (1 g/day) trials in mixed populations often miss significance. High-dose EPA-only (REDUCE-IT) produced dramatic cardiovascular benefits. The omega index — ideally kept above 8% (most North Americans are at 4–5%) — is increasingly viewed as the relevant biomarker for guiding omega-3 repletion strategies.
Fish Oil vs. Algae Oil: Bioavailability, Purity, and Sustainability
Fish do not synthesize omega-3s — they bioaccumulate DHA and EPA from microalgae and zooplankton at the base of the marine food chain. This means algae oil is not merely a "vegan alternative" — it is the original source. Both delivery forms can provide equivalent plasma DHA and EPA levels when matched for dose, but meaningful differences in purity, sustainability, and specific fatty acid ratios distinguish them.
Fish Oil: Strengths and Limitations
Fish oil is the most extensively studied delivery vehicle, with the largest clinical trial database. High-quality fish oils processed by molecular distillation and certified by the International Fish Oil Standards (IFOS) program are reliably free of mercury, PCBs, and dioxins. However, lower-quality fish oils — which make up the majority of the mass-market supplement aisle — can contain oxidized lipids that may actually increase cardiovascular risk markers. The key quality indicator is TOTOX value (total oxidation): IFOS-certified products require TOTOX ≤26; a value >50 indicates rancid oil that should be discarded. Fresh fish oil should smell mildly of fish or have a neutral odor — pungent "fishy" odor indicates oxidation.
Algae Oil: The Case for Direct-Source Supplementation
Pharmaceutical-grade algae oil (typically from Schizochytrium or Crypthecodinium cohnii microalgae) provides DHA and EPA without the contamination risks or sustainability concerns of wild fish. A 2012 bioequivalence study (Arterburn et al.) found algae DHA raised plasma DHA levels equivalently to cooked salmon. Algae oil is now available in high-potency formulations (600+ mg DHA per softgel) and is the preferred choice for individuals with fish allergies, ethical concerns, or elevated contamination risk concerns. The main limitation historically has been lower EPA content relative to DHA — though newer algae oils increasingly offer EPA alongside DHA.
Triglyceride vs. Ethyl Ester Form
Omega-3 supplements come in three primary molecular forms: natural triglycerides (TG), re-esterified triglycerides (rTG), and ethyl esters (EE). Bioavailability studies consistently show TG and rTG forms absorb 20–70% better than EE forms when taken without fat. Pharmaceutical EPA-EE (Vascepa/Lovaza) achieve high plasma levels by prescription dosing and patient compliance, but over-the-counter EE products require dietary fat co-ingestion to approach TG-form absorption. For OTC supplementation, look for "triglyceride form" or "re-esterified triglyceride" on the label.
LongevityLab Omega-3 Protocol
- Target dose: 2–3 g/day combined EPA+DHA (not "fish oil" — read the active ingredient label)
- Timing: Split across two fat-containing meals (breakfast and dinner) for optimal absorption and tolerability
- Form preference: Re-esterified triglyceride (rTG) > natural TG > ethyl ester; algae oil equivalent for DHA
- Purity standard: IFOS 5-star certification, TOTOX value <26, heavy metals below detection threshold
- Baseline testing: Omega index test (OmegaQuant or Genova) before starting; target ≥8% RBC EPA+DHA (most North Americans are 4–5%)
- Cardiovascular risk: If elevated triglycerides or established CVD, discuss prescription EPA (Vascepa) with a physician for 4 g/day dosing
- Storage: Refrigerate after opening; discard if strong fishy odor develops (oxidation indicator)
- Vegetarian/vegan: Algae-derived DHA+EPA (e.g., Life's OMEGA, Nordic Naturals Algae Omega) provides equivalent bioavailability
- Blood thinners: Consult physician if on anticoagulants — omega-3s have mild anti-platelet effects, though clinical bleeding risk at supplement doses is minimal
Algae Omega-3: Vegan, Contaminant-Free DHA+EPA
For those avoiding fish products or concerned about ocean contamination, pharmaceutical-grade algae oil delivers bioequivalent DHA — and increasingly EPA — directly from the microalgal source.
As an Amazon Associate, LongevityLab earns from qualifying purchases. Affiliate links help support free content.